Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸ P-TRG(Platelet-Thrombosis Research Group) 2023 : 2023-10-28
±³À°ÀÏÀÚ : 2023-10-28
±³À°Àå¼Ò : ¼¿ï ÄÚ¿¢½º, 3F ÄÁÆÛ·±½º·ë(³²) E
±³À°ÁÖÁ¦ : P-TRG(Platelet-Thrombosis Research Group) 2023
ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸
´ã´çÀÚ : Á¶¿¹¸®
¿¬¶ôó : 02-582-8222
À̸ÞÀÏ : yehc@kscvi.org
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 22ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:00~09:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) STOPDAPT-3: An Aspirin-free Antithrombotic Strategy for Percutaneous Coronary Intervention ¿øÈ£¿¬(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:10~09:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Optimal antiPlatelet Therapy for high Bleeding and Ischemic RISK patients - OPT-BIRISK Á¶¼º¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:20~09:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Aspirin versus Clopidogrel for Long-Term Maintenance Monotherapy after Percutaneous Coronary Intervention: The HOST-EXAM Extended Study °ÁöÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:30~09:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Bivalirudin Plus a High-dose Infusion versus Heparin Monotherapy in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Randomised Trial Â÷Á¤ÁØ(°í·ÁÀÇ´ë)
Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:40~10:00 Discussion ()
ÈÞ½Ä 10¿ù 28ÀÏ 10:00~10:20 Coffee Break ()
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 10:20~10:35 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Stent Optimization Strategy May Modify DAPT(Dual Antiplatelet Therapy) ÀÌ»óÇù(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 10:35~10:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Genotyping/Platelet Reactivity Guided DAPT(Dual Antiplatelet Therapy) Duration in Selected Patients ¹®À翬(Â÷ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 10:50~11:05 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Inflammatory Activity and Platelet Reactivity and Its Potential Effect on DAPT(Dual Antiplatelet Therapy) Á¤¿µÈÆ(Áß¾ÓÀÇ´ë)
Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:05~11:20 Discussion ()
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:20~11:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antithrombotic Therapy after TAVR(Transcatheter Aortic Valve Replacement) °µµÀ±(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:30~11:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antithrombotic Therapy after LAAO(Left Atrial Appendage Occlusion) ½Å½Â¿ë(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:40~11:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antithrombotic Therapy in ASD(Atrial Septal Defect)/PFO(Patent Foramen Ovale) Closure ÀÌ¿ÀÇö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:50~12:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antithrombotic Therapy after Peripheral and Aorta Intervention ±è¿øÈ£(À»ÁöÀÇ´ë)
Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 12:00~12:20 Discussion ()
±âŸ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 12:20~12:30 P-TRG ÃÑȸ ()
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 12:30~12:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) PTRG-DES Consortium: Experiences from the Largest Registry of VerifyNow Test (Platelet Function and Genotype‐Related Long‐Term Prognosis in Drug‐Eluting Stent–Treated Patients With Coronary Artery Disease) Á¶Á¤·¡(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 12:50~13:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Cutting Edge Care of Pitavastatin with Ezetimibe Combination Therapy Á¶»óÈ£(ÇѸ²ÀÇ´ë)
Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 13:10~13:30 Discussion ()
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 13:30~13:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Use of TEG in ASCVD(Atherosclerotic Cardiovascular Disease) ±èÇö±¹(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 13:45~14:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Evidences of Dual Pathway Inhibition Using Factor X Inhibitior in CAD(Coronary Artery Disease) ¾ÈÁØÈ£(Àü³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 14:00~14:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Factor XI Inhibitior at Present and Future Perspectives ÀÌ»ó¿±(Áß¾ÓÀÇ´ë)
Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 14:15~14:30 Discussion ()
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 14:30~14:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Implication of CYP2C19 Genotype and HPR on Clinical Prognosis in Korean Patients ¾È¼º±Õ(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 14:45~15:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Sex Differences in Midterm Prognostic Implications of High Platelet Reactivity after PCI(Percutaneous Coronary Intervention) with DES(Drug-eluting Stent) ½ÅÀº¼®(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 15:00~15:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Implication of Diabetic Status on Platelet Reactivity and Clinical Outcomes after Drug-Eluting Stent Implantation ¼Á¤¿ø(¼¿ïÀÇ´ë)
Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 15:15~15:30 Discussion ()
ÈÞ½Ä 10¿ù 28ÀÏ 15:30~15:50 Coffee Break ()
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 15:50~16:02 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Balancing Bleeding and Thrombosis Risks in ECMO(Extracorporeal Membrane Oxygenation)-supported Acute Myocardial Infarction Patients: A Case Study ¾ÈÇü¹ü(ºÐ´ç¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 16:02~16:24 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Successful Recovery of Maligant Acute rt MCA(Middle Cerebral Artery) infarction Combined with RCA(right coronary artery) ST Segment Elevation Myocardial Infarction ÃÖ¼ºÈ¯(ÀÎÇÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 16:24~16:36 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) A Case of Acute Multiple Stent Thrombosis after PCI(Percutaneous Coronary Intervention) Àå´öÇö(ºÎõ¼¼Á¾º´¿ø)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 16:36~16:48 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Relapsed NSTEMI(Non-ST Segment Elevation Myocardial Infarction) due to Acute Gastrointestinal Bleeding after NSTEMI(Non-ST Segment Elevation Myocardial Infarction) ±èµµ¿ø(Á¤ÇÑ»ù³»°úÀÇ¿ø)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 16:48~17:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Acute Myocardial Infarction Patient with Severe Thrombocytopenia ±èÇü¿À(»ïÀ°¼¿ïº´¿ø)
±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 17:00~17:12 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Successful PCI(Percutaneous Coronary Intervention) in Hemophilia A Patient with Acute Myocardial Infarction Occurring at a Prior Documented Minimal Coronary Artery Lesion ¹Ú»ó¹Î(³ë¿øÀ»Áö´ëÇб³º´¿ø)
±âŸ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 17:12~17:20 Best Presentation ½Ã»ó ()